Register for our free email digests:
Ramsey Baghdadi
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Ramsey Baghdadi
Medicare-For-Hmmm: A Year Of House Hearings Show Democratic Disunity
Four House hearings show how far away even many Democrats are from supporting a single payer system in the US.
US FDA's New Neurology Leadership Likely To Face Two Big Reviews In 2020
Eric Bastings will lead Division of Neurology I, which is expected to handle Biogen’s Alzheimer’s drug aducanumab and Sarepta’s refiling of golodirsen for DMD next year.
For Biopharma, There May Be Only One Race To Watch In 2020
Senate Majority Leader McConnell is the one constant keeping drug price controls from gaining any legislative traction.
A Short Eulogy For The Rebate Rule
The rebate rule is dead, but we should pay tribute to the failed endeavor.
Drug Price Transparency Bills May Be Empty Calories
Price justification legislation is advancing in both chambers of Congress. But CBO scores them as no savings.
CREATES Act Approaches Finish Line But Legislation May Fail To Launch
Broad bipartisan support and billions in projected savings mean that bill may finally pass. But whether it will work as intended to improve generic access to market remains as questionable as ever.